Floatz logo

Lansoprazole

Gastroesophageal Reflux Disease

Children's Mercy Hospital Kansas CitySmall moleculePhase 4 / ApprovedDormant
BB
68/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
54/ 100
Competitive Position
89/ 100

Competitive context

1 Active assets in the Gastroesophageal Reflux Disease cohort.

Asset / SponsorPhaseRating
Pantoprazole
Children's Mercy Hospital Kansas City
Phase 4BB
Midazolam
Children's Mercy Hospital Kansas City
Phase 4BB
Dexlansoprazole
National Cheng-Kung University Hospital
Phase 4BB
Tannic Acid
Hospital Infantil Cândido Fontoura
Phase 3BB
Lidocaine
Hospital Infantil Cândido Fontoura
Phase 3BB

View all 17 →

Same molecule, other indications

Lansoprazole is also rated in:

obesity disorderDormant
BB
Indicative · Phase 4
69 / 100
View asset →
metabolic dysfunction-associated steatotic liver diseaseDormant
BB
Indicative · Phase 4
65 / 100
View asset →
breast cancerActive
B
Indicative · Phase 3
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →